Alliances
The technologies developed by LAB10x will be applied to generate and analyze “anonymized” patient data sets to improve patient outcomes and accelerate medical research and pharmaceutical R&D.
Spero Therapeutics, Inc. announced that it entered into a collaboration with the Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis, an indication that is designated as a critical concern by the World Health Organization.
Partnership secures access to reserved cGMP capacity and resources at Yposkesi for manufacturing to support the global development and commercialization of Axovant’s gene therapy programs
There are currently no oral antibiotics specifically approved for use to treat pulmonary NTM infections. If successfully developed, SPR720 has the potential to address an important unmet need as the first oral antibiotic.
Scope of the collaboration expands to include up to 12 rare disease targets and includes Arcturus nucleic acid technologies to enable mRNA, DNA, and siRNA therapeutics
The focus will be on discovering drugs that use the body’s natural protein control processes.
Retrophin, Inc. announced that it has entered into a three-way Cooperative Research and Development Agreement with the National Institutes of Health’s National Center for Advancing Translational Sciences and patient advocacy foundation Alagille Syndrome Alliance to collaborate on research efforts aimed at the identification and development of potentially novel therapeutics for Alagille syndrome.
Vivoryon Therapeutics AG and goetzpartners, announced their collaboration to explore the expansion of Vivoryon’s proprietary platform based on its Glutaminyl-peptide cyclotransferase-like protein technology into the field of immuno-oncology.
The companies will combine their research expertise to develop BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations including V600 BRAF mutations, non-V600 B-RAF mutations, and RAF fusions.
Amgen hopes the data will provide insights into specific diseases that will help develop new drugs.
PRESS RELEASES